Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.

Also called NCT01386671

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 203 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01386671
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01386671. Randomized; double masking; primary purpose treatment. Start 2014-06 (actual); primary completion 2016-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes
Acronym
COMET
Intervention (Drug)
Metformin glycinate
Intervention (Drug)
Metformin hydrochloride
Lead sponsor
Laboratorios Silanes S.A. de C.V. (class: industry)

Record details

Record id
cardio:ct-nct01386671
Content hash
8db5c25c8bd98a5653284afa9f9d0bfcf5799c6e17d66596f3c84ea733ae1165